Tolnaftate Antifungal
Tolnaftate
Geri-care Pharmaceuticals, Corp
Human Otc Drug
NDC 57896-199Tolnaftate Antifungal also known as Tolnaftate is a human otc drug labeled by 'Geri-care Pharmaceuticals, Corp'. National Drug Code (NDC) number for Tolnaftate Antifungal is 57896-199. This drug is available in dosage form of Powder. The names of the active, medicinal ingredients in Tolnaftate Antifungal drug includes Tolnaftate - 1 g/100g . The currest status of Tolnaftate Antifungal drug is Active.
Drug Information:
| Drug NDC: | 57896-199 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Tolnaftate Antifungal |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Tolnaftate |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Geri-care Pharmaceuticals, Corp |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Powder |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | TOLNAFTATE - 1 g/100g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Aug, 2011 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 24 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part333C |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Geri-Care Pharmaceuticals, Corp
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 313422
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| UPC: | 0357896199456
|
| UPC stands for Universal Product Code. |
| UNII: | 06KB629TKV
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 57896-199-45 | 45 g in 1 BOTTLE, DISPENSING (57896-199-45) | 01 Aug, 2011 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose section antifungal
Product Elements:
Tolnaftate antifungal tolnaftate starch, corn talc tolnaftate tolnaftate
Indications and Usage:
Indications and uses section uses for effective treatment of most athlete's foot(linea pedis) and ring worm (thea corporis) for effective relief of itchy, scaly skin between the toes clears up most athlete's foot infection and with daily use helps keep it from coming back
Warnings:
Warnings section warnings for external use only do not use on children under 2 years of age except under the advice and supervision of a doctor. when using this product avoid contact with the eyes stop use and consult a doctor if irritation occurs there is no improvement within 4 weeks other information store at room temperature
Dosage and Administration:
Dosage and administration section drug facts directions shake well before use clean the affected area and dry thoroughly apply a thin layer of the product over affected area twice daily (morning and night) or as directed by a doctor supervise children in the use of this product use daily for 4 weeks. if condition persists longer, consult a doctor for athlete's foot pay special attention to the spaces between the toes wear well ventilated shoes change shoes and socks at least once a day to prevent athlete's foot, clean and dry feet thoroughly. apply as above once or twice daily. this product is not effective on the scalp or nails.
Package Label Principal Display Panel:
Package label ndc 57896-199-45 gericare tolnaftate antifungal powder 1 percent cures and prevents most athlete's foot compare to the active ingredient of tinactin this product is not manufactured or distributed by the owner of the registered trademark tinactin distributed by geri-care pharmaceuticals 1650 63rd street brooklyn ny 11204 rev. 11/10 310-29009-0 net wt. 45g (1 1/2 oz.) tolnaftate antifungal label